Surrogate markers of liver fibrosis are needed as an alternative to liver biopsy, which is invasive and life-threatening. Peripheral blood fibrocytes (PBF) are considered to be involved in systemic fibrogenic processes. We measured the level of PBF in patients with chronic hepatitis C by enrolling 70 patients affected with chronic hepatitis C, 20 patients with HCV-positive decompensated cirrhosis and 30 healthy volunteers. All patients underwent liver biopsy and Fibroscan for fibrosis assessment.
Circulating fibrocytes as a marker of liver fibrosis in chronic hepatitis C
Nunnari G
;Vancheri C;La Rosa C;Cacopardo B
2010-01-01
Abstract
Surrogate markers of liver fibrosis are needed as an alternative to liver biopsy, which is invasive and life-threatening. Peripheral blood fibrocytes (PBF) are considered to be involved in systemic fibrogenic processes. We measured the level of PBF in patients with chronic hepatitis C by enrolling 70 patients affected with chronic hepatitis C, 20 patients with HCV-positive decompensated cirrhosis and 30 healthy volunteers. All patients underwent liver biopsy and Fibroscan for fibrosis assessment.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0168827810610690-main (1).pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
47.15 kB
Formato
Adobe PDF
|
47.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.